Chart-Typ:
Zeitraum:
| Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
20.07.2026 / 16:41 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen |
| Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders | TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen |
| Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
30.04.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen |
| BTCS, Inc.: BTCS Inc. Appoints Chris Janis to Its Board of Directors | WAYNE, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- BTCS Inc. (Nasdaq: BTCS) ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, a company focused on blockchain infrastructure... ► Artikel lesen |
| XFRA CAPITAL ADJUSTMENT INFORMATION - 28.05.2026 | Das Instrument JGNR IE0005FKEK99 JPM-GSS BD UE A ETF wird cum Kapitalmassnahme gehandelt am 28.05.2026 und ex Kapitalmassnahme am 29.05.2026 The instrument JGNR IE0005FKEK99 JPM-GSS BD UE A ETF is traded... ► Artikel lesen |
| BTCS, Inc.: BTCS Reports Gross Profit of $1.0 Million and 47% Gross Margin for First Quarter 2026 | WAYNE, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- BTCS Inc. (Nasdaq: BTCS) ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, a company focused on blockchain infrastructure... ► Artikel lesen |
| MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF | Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations 90% of patients had no [60%] or mild [30%] cough~450 total inhalations administered... ► Artikel lesen |
| MannKind Announces $50 Million Private Placement | DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through... ► Artikel lesen |
| MannKind Announces FDA Approval of Furoscix ReadyFlow, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease | Transformative delivery option that may support earlier management of worsening fluid overload with a self-administered option designed for use outside the hospital settingDelivers IV-equivalent diuretic... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARB IOT GROUP LIMITED finden Sie auf Wallstreet Online.